Clinical Trial Update: Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant chemoradiation with Camrelizumab and Nimotuzumab for initially inoperable esophageal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Toxicity, Drug | Phase 2 | Status: COMPLETED